BioPharmSignal logoBioPharmSignal

Biotech News

Paratek Pharmaceuticals Announces Positive Results for NUZYRA® Therapeutic Efficacy Studies in Inhalation Anthrax Triggering Additional Procurement under BARDA Project BioShield Contract

Paratek Pharmaceuticals (PRTK)Paratek PharmaceuticalsCompany update

First of two Pivotal Efficacy Studies support future sNDA submission for Treatment of Pulmonary Anthrax

Oral NUZYRA Tablets Produced in the U.S. as a Result of the Company's Onshoring Initiative were Procured by BARDA

KING OF PRUSSIA, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Paratek...

Related news

PRTKParatek Pharmaceuticals2024-03-05 06:45 EST

Paratek Pharmaceuticals Announces Positive Efficacy Data for NUZYRA® as Post-Exposure Prophylaxis of Inhalational Anthrax, Triggering Additional Procurement under BARDA Project BioShield Contract

PRTKParatek Pharmaceuticals2022-12-19 07:30 EST

Paratek Pharmaceuticals Announces Positive Top Line Data from Pilot Efficacy Study for the Treatment of Pulmonary Anthrax and Acceptance of the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield

View all latest news

Paratek Pharmaceuticals

Paratek Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

PRTKParatek Pharmaceuticals2026-04-16 07:30 EST

Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2026

PRTKParatek Pharmaceuticals2026-03-18 07:00 EST

Paratek Pharmaceuticals Completes Combination with Radius Health, Expanding Its Multi-Product Specialty Commercial Platform

PRTKParatek Pharmaceuticals2026-02-24 07:30 EST

Paratek Pharmaceuticals Announces Positive Results for NUZYRA® Therapeutic Efficacy Studies in Inhalation Anthrax Triggering Additional Procurement under BARDA Project BioShield Contract

PRTKParatek Pharmaceuticals2025-10-17 07:30 EST

Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at IDWeek 2025 and CHEST 2025

PRTKParatek Pharmaceuticals2025-05-21 08:26 EST

Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States